

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
<p>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</p> <p><b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.</b></p>					
1. REPORT DATE (DD-MM-YYYY) 10/26/2017		2. REPORT TYPE Poster		3. DATES COVERED (From - To) 10/26/2017-10/29/2017	
4. TITLE AND SUBTITLE Melanoma or Pseudo-melanoma? Change in a pigmented lesion after application of topical 5-Fluorouracil.				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Capt Kelly A Haeusler				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				8. PERFORMING ORGANIZATION REPORT NUMBER  17388	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release. Distribution is unlimited.					
13. SUPPLEMENTARY NOTES American Society of Dermatopathology, Baltimore, MD, 26-29 October 2017.					
14. ABSTRACT 5-fluorouracil (5-FU) is a topical chemotherapeutic agent used to treat actinic keratosis and superficial basal cell carcinomas. Common side effects include photosensitivity, erythema, ulceration and rarely hyperpigmentation. We present the case of a 56 year old, skin type 1 female that demonstrated a morphologic change in a pigmented lesion following topical field therapy with 5-FU for actinic damage on the trunk. After four weeks of twice daily application, a previously benign appearing pigmented lesion displayed a change in clinical morphology that included border irregularity, pigmentary change, scaling and erythema. A biopsy of the lesion demonstrated a poorly circumscribed and asymmetric compound proliferation of melanocytes with irregularly distributed junctional nests, solitary units and prominent pagetoid scatter. The epidermis showed large clusters of necrotic keratinocytes, dense pigment and sub-epidermal clefting. Fluorescent in-situ hybridization (FISH) was performed on additional sections and did not demonstrate chromosomal aberrations. Review of the literature demonstrated few reports of eruptive lentigo-maligna and atypical nevi occurring in patients undergoing therapy with oral 5-FU suggesting immunosuppression induced melanocytic proliferations or malign					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Clarice Longoria
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (Include area code) 210-292-7141





## Melanoma or Pseudo-melanoma?

### Change in a pigmented lesion after application of topical 5-Fluorouracil.

Authors: Capt Kelly A. Haeusler, MD, Capt Jacob R. Hall, MD, Maj Caitlin M. Seykora, DO, MAJ Margaret J. Abuzeid, MD, COL Scott R. Dalton, DO.

#### Abstract

5-fluorouracil (5-FU) is a topical chemotherapeutic agent used to treat actinic keratosis and superficial basal cell carcinomas. Common side effects include photosensitivity, erythema, ulceration and rarely hyperpigmentation. We present the case of a 56 year old, skin type 1 female that demonstrated a morphologic change in a pigmented lesion following topical field therapy with 5-FU for actinic damage on the trunk. After four weeks of twice daily application, a previously benign appearing pigmented lesion displayed a change in clinical morphology that included border irregularity, pigmentary change, scaling and erythema. A biopsy of the lesion demonstrated a poorly circumscribed and asymmetric compound proliferation of melanocytes with irregularly distributed junctional nests, solitary units and prominent pagetoid scatter. The epidermis showed large clusters of necrotic keratinocytes, dense pigment and sub-epidermal clefting. Fluorescent in-situ hybridization (FISH) was performed on additional sections and did not demonstrate chromosomal aberrations. Review of the literature demonstrated few reports of eruptive lentigo-maligna and atypical nevi occurring in patients undergoing therapy with oral 5-FU suggesting immunosuppression induced melanocytic proliferations or malignant transformation. No reports were found with topical 5-FU therapy.

This case illustrates the difficulty when lesions are biopsied in a treatment field during or immediately following topical 5-FU therapy. The histopathologic features were consistent with melanoma; however, clinical suspicion for melanoma was not present until therapy was near completion. This raises a question as to whether this lesion was a melanoma that was not clinically apparent prior to therapy; was a benign lesion that transformed during therapy or is a pseudo-melanoma as the FISH studies showed no aberrations.

#### Case Report



The patient is a 56 year old, skin type 1 female that demonstrated a morphologic change in a pigmented lesion following topical field therapy with 5-FU for actinic damage on the trunk. After four weeks of twice daily application, a previously benign appearing pigmented lesion displayed a change in clinical morphology that included border irregularity, pigmentary change, scaling and erythema.

#### Histopathology


A biopsy of the lesion demonstrated a poorly circumscribed and asymmetric compound proliferation of melanocytes with irregularly distributed junctional nests, solitary units and prominent pagetoid scatter. The epidermis showed large clusters of necrotic keratinocytes, dense pigment and sub-epidermal clefting.



(A.) 7mm thin papule with irregular borders and multiple areas of variegated tan to dark brown color with slight induration and crusting.



(B) Upward scatter of pigmented melanocytes. Clefting artifact at the dermal epidermal junction. (Hematoxylin and Eosin Stain, 100x magnification) (C) Mart-1 immunostain highlights the asymmetric melanocytic proliferation (100x magnification).



(D) H&E and (E) Mart-1 immunostain showing nests and solitary melanocytes with upward scatter (125x magnification).

#### Discussion

Eruptive melanocytic lesions with atypia in previously benign appearing melanocytic lesions have been described in patients undergoing systemic 5 FU therapy<sup>1,2</sup>. The pathogenesis is believed to be due to immunosuppression and subsequent melanocytic proliferation. The mechanism of action of 5 FU orally and topically are identical, which theoretically could induce the same immunosuppression, but only in the area of application as very little topical 5-FU is absorbed systemically.

Previous cases of oral 5 FU induced eruptive melanocytic lesions with atypia have described similar histopathologic features. These include large, atypical melanocytes arranged in nests and solitary units, epidermal atrophy and marked solar elastosis<sup>1-3</sup>. The differences between the current case and previous reports are the prominent pagetoid scatter and sub-epidermal clefting, which could be attributed to the direct application of the 5 FU. Pagetoid scatter of melanocytes has been described in traumatized nevi<sup>4</sup>.

Flourescent in-situ hybridiation (FISH) can be a helpful adjuvant test in categorizing atypical melanocytic proliferations into benign or malignant based on aberrations (gains or losses) in loci on chromosomes 6, 9 and 11<sup>5,6</sup>. The reported sensitivity and specificity is 86% and 97%, respectively; however, melanomas can be negative for FISH aberrations<sup>5</sup>. This case was negative for the FISH alterations. FISH analysis of 5-FU induced melanocytic atypia has not been described. 5-FU alters DNA synthesis and repair, but its effects on melanocytes has not been evaluated. The significance of a negative FISH in this setting is unclear.

This case illustrates the difficulty when lesions are biopsied in a treatment field during or immediately following topical 5-FU therapy. The histopathologic features were consistent with melanoma; however, melanoma was not considered until therapy was near completion. This raises the question as to whether this lesion was a melanoma not clinically apparent prior to therapy; was a benign nevus or lentigo that transformed during therapy or a therapy induced pseudo-melanoma as the FISH studies showed no aberrations. The lesion was ultimately treated as a melanoma due to the architectural and cytologic features and the patient had a wide local excision to ensure complete removal.

#### References

1. Bogenrieder T, Wetzels C, Scholmerich J, Landthaler M, Stolz W. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? *Dermatology (Basel, Switzerland)*. 2002;205(2):174-175.
2. Rodriguez-Blanco I, Ginarte Val M, Peteiro C, Toribio J. Multiple atypical naevi after systemic 5-fluorouracil. *Journal of the European Academy of Dermatology and Venerology*. JEADV. Jul 2007;21(6):822-825.
3. Fukushima S, Hattori N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. *The British journal of dermatology*. Sep 2004;151(3):698-700.
4. Seim MA, Volmer RT, Herman CM, Pham TT, Turner JW. Melanocytic nevi with nonsurgical trauma: a histopathologic study. *The American journal of dermatopathology*. Apr 2007;29(2):134-136.
5. North JP, Garrido MC, Kraljic NA, LeBoit PE, McCalmont TH, Bastian BC. Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases. *The American journal of surgical pathology*. Jun 2014;38(6):824-831.
6. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. *The American journal of surgical pathology*. Aug 2009;33(8):1146-1156.